Key facts
- PhaseV (Healthcare Technology Systems)’s last known valuation is $21.6M (Oct 2023).
- It has raised $65.0M; the latest was Early Stage VC ($50.0M) in May 2025.
- Notable investors include Accel, Insight Partners (New York), Viola Ventures, Exor, GETTY — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for PhaseV (Healthcare Technology Systems)
- ·The full record, as it builds
Funding rounds
No funding rounds for PhaseV (Healthcare Technology Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PhaseV (Healthcare Technology Systems)
Developer of an adaptive clinical trial platform designed to improve the effectiveness of clinical trials. The company's platform specializes in continuously advising on the best adaptations according to the real-time statistical and causal analysis of the accumulated data, enabling researchers to optimize trials, discover new signals hidden in the data, and provide the best possible treatments to patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 37
- Website
- phasevtrials.com/
- Ownership
- Privately Held (backing)
PhaseV (Healthcare Technology Systems) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhaseV (Healthcare Technology Systems) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhaseV (Healthcare Technology Systems) in its N-PORT filings yet. We sweep new filings monthly.